Methods of treating resistant cancer therapeutic agents ERBB

A therapeutic agent anti-ErbB and an anti-MET therapeutic agent for use in treating a cancer in a subject that has developed resistance to treatment with anti-ErbB therapeutic agent, wherein the subject has an amplification of the MET gene wherein the anti-ErbB therapeutic agent is gefitinib, erlotinib, lapatinib, PF00299804, CI-1033, EKB-569, BIBW2992, ZD6474, AV-412 or HKI-272, and wherein the anti-MET therapeutic agent is PHA-665752, SU11274, SU5416, PF-02341066, XL-880 or MGCD265.